Skip to main content
. Author manuscript; available in PMC: 2019 Dec 9.
Published in final edited form as: Cancer. 2016 Sep 20;122(23):3641–3649. doi: 10.1002/cncr.30317

TABLE 4.

Treatment-Emergent Adverse Events Considered Related to Study Drug (>10%): All Grades

No. of Patients (%)
Dalantercept Dose
Preferred AE Term 80 mg, N = 2 0.6 mg/kg, N = 13 1.2 mg/kg, N = 31 Overall, N = 46
Patients with ≥ 1 AE 1 (50) 13 (100) 27 (87.1) 41 (89.1)
Anemia 0 (0) 2 (15.4) 10 (32.3) 12 (26.1)
Fatigue 1 (50) 3 (23.1) 7 (22.6) 11 (23.9)
Peripheral edema 0 (0) 2 (15.4) 9 (29) 11 (23.9)
Headache 0 (0) 3 (23.1) 5 (16.1) 8 (17.4)
Hyponatremia 1 (50) 0 (0) 6 (19.4) 7 (15.2)
Pleural effusion 0 (0) 1 (7.7) 4 (12.9) 5 (10.9)

Abbreviation: AE: adverse event.